Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.97 |
| ▸ | CHRNG | P07510 | 5/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.97 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.97 |
| ▸ | CHRND | Q07001 | 5/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL31748783 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL29682406 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL5075866 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL1237221 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL29420039 | 1.00 | SLC6A2 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL12499296 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL30679332 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL38777 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL300444 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 | |
| Bupropion SCHEMBL29354885 | 0.98 | SLC6A3 (1.00) | SLC6A2ALDH1A1BLMSMN1; SMN2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4757 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144764-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144765-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094687-A | Compounds and combinations thereof for the treatment of neurological and psychiatric disorders | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107265-A1 | PHARMACEUTICAL DOSAGE FORMS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260130871-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-14 | — | — | US | claimed |
| US-20260124195-A1 | BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS | ANTECIP BIOVENTURES II LLC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260102354-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NALTREXONE AND/OR BUPROPION | NALPROPION PHARMACEUTICALS LLC (US) | 2026-04-16 | — | — | US | claimed |
| US-12599576-B2 | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan | ANTECIP BIOVENTURES II LLC (US) | 2026-04-14 | — | — | US | claimed |
| US-12599563-B1 | Pharmaceutical formulations comprising naltrexone and/or bupropion | NALPROPION PHARMACEUTICALS LLC (US) | 2026-04-14 | — | — | US | claimed |
| US-20260097006-A1 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | ANTECIP BIOVENTURES II LLC (US) | 2026-04-09 | — | — | US | claimed |
| WO-1995022324-A1 | TREATMENT OF MIGRAINE HEADACHES AND FORMULATIONS | PINSKER WALTER (US) | 1995-08-24 | — | — | WO | claimed |
| US-5427798-A | One year shelf life | BURROUGHS WELLCOME CO. (US) | 1995-06-27 | — | — | US | claimed |
| EP-0656775-A1 | SUSTAINED RELEASE TABLETS CONTAINING BUPROPION | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | claimed |
| WO-1995003791-A1 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BUPROPION | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-09 | — | — | WO | claimed |
| US-5358970-A | Inclusion of an acidic compound inhibits degradation of antidepressant and increases shelf life | BURROUGHS WELLCOME CO. (US) | 1994-10-25 | — | — | US | claimed |
| WO-1994004138-A1 | SUSTAINED RELEASE TABLETS CONTAINING BUPROPION | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-03-03 | — | — | WO | claimed |
| US-RE33994-E | Pharmaceutical delivery system | BURROUGHS WELLCOME CO. (US) | 1992-07-14 | — | — | US | claimed |
| EP-0467488-A2 | Composition for the controlled discharge of an active ingredient | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-01-22 | — | — | EP | claimed |
| EP-0171227-B1 | USE OF PROPIOPHENONE COMPOUND | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-11-02 | — | — | EP | claimed |
| EP-0171227-A1 | Use of propiophenone compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-12 | — | — | EP | claimed |